BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ganaplacide/lumefantrine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ganaplacide/lumefantrine\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07811908-11261@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Ganaplacide/lumefantrine: Phase 2 readout est. (NCT07811908)
DESCRIPTION:Ganaplacide/lumefantrine\, phase 2\, Malaria.\nStudy: Platform 
 Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Parti
 cipants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)\nEsti
 mated primary completion: 4 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ganaplacide-lumefantrine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07811908
URL:https://assetmemo.bio/drug/ganaplacide-lumefantrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
